Last reviewed · How we verify
MG56 Mannosylated 1000 sublingual
MG56 Mannosylated 1000 sublingual is designed to enhance immune response through targeted delivery to immune cells.
MG56 Mannosylated 1000 sublingual is designed to enhance immune response through targeted delivery to immune cells. Used for Immune modulation for the treatment of unspecified immunological disorders.
At a glance
| Generic name | MG56 Mannosylated 1000 sublingual |
|---|---|
| Sponsor | Inmunotek S.L. |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
The mannosylation of the drug allows it to bind specifically to mannose receptors on immune cells, potentially improving its efficacy in stimulating an immune response.
Approved indications
- Immune modulation for the treatment of unspecified immunological disorders
Common side effects
- Local irritation
Key clinical trials
- Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MG56 Mannosylated 1000 sublingual CI brief — competitive landscape report
- MG56 Mannosylated 1000 sublingual updates RSS · CI watch RSS
- Inmunotek S.L. portfolio CI